UBS AM’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.22M | Sell |
357,728
-2,185
| -0.6% | -$21.1K | ﹤0.01% | 1589 |
|
|
2026
Q1 | $2.67M | Buy |
359,913
+9,066
| +3% | +$95.4K | ﹤0.01% | 1901 |
|
|
2025
Q4 | $4.13M | Sell |
350,847
-2,411
| -0.7% | -$26K | ﹤0.01% | 1564 |
|
|
2025
Q3 | $2.73M | Sell |
353,258
-228,529
| -39% | -$1.6M | ﹤0.01% | 1625 |
|
|
2025
Q2 | $4.25M | Buy |
581,787
+84,336
| +17% | +$681K | ﹤0.01% | 1788 |
|
|
2025
Q1 | $4.72M | Sell |
497,451
-148,660
| -23% | -$1.86M | ﹤0.01% | 1606 |
|
|
2024
Q4 | $10.6M | Buy |
646,111
+42,895
| +7% | +$666K | ﹤0.01% | 1222 |
|
|
2024
Q3 | $8.9M | Sell |
603,216
-23,239
| -4% | -$364K | ﹤0.01% | 1287 |
|
|
2024
Q2 | $8.69M | Buy |
626,455
+205,436
| +49% | +$2.91M | ﹤0.01% | 1198 |
|
|
2024
Q1 | $6.62M | Buy |
421,019
+17,267
| +4% | +$267K | ﹤0.01% | 1147 |
|
|
2023
Q4 | $6.53M | Sell |
403,752
-13,734
| -3% | -$225K | ﹤0.01% | 1143 |
|
|
2023
Q3 | $5.14M | Buy |
417,486
+22,021
| +6% | +$327K | ﹤0.01% | 1192 |
|
|
2023
Q2 | $6.89M | Hold |
395,465
| – | – | ﹤0.01% | 1099 |
|
|
2023
Q1 | $6.89M | Buy |
+395,465
| New | +$5.63M | ﹤0.01% | 1099 |
|
|
2022
Q4 | – | Sell |
-377,967
| Closed | -$3.25M | – | 2690 |
|
|
2022
Q3 | $3.25M | Sell |
377,967
-33,206
| -8% | -$330K | ﹤0.01% | 1353 |
|
|
2022
Q2 | $3.35M | Sell |
411,173
-13,249
| -3% | -$126K | ﹤0.01% | 1375 |
|
|
2022
Q1 | $5.16M | Sell |
424,422
-5,120
| -1% | -$108K | ﹤0.01% | 1339 |
|
|
2021
Q4 | $14.7M | Sell |
429,542
-8,554
| -2% | -$335K | 0.01% | 995 |
|
|
2021
Q3 | $21.1M | Sell |
438,096
-10,305
| -2% | -$477K | 0.01% | 848 |
|
|
2021
Q2 | $20.3M | Sell |
448,401
-11,840
| -3% | -$525K | 0.01% | 882 |
|
|
2021
Q1 | $22.2M | Buy |
460,241
+5,169
| +1% | +$269K | 0.01% | 833 |
|
|
2020
Q4 | $24.5M | Sell |
455,072
-12,890
| -3% | -$582K | 0.01% | 792 |
|
|
2020
Q3 | $17.3M | Buy |
467,962
+2,458
| +0.5% | +$91.4K | 0.01% | 813 |
|
|
2020
Q2 | $14.4M | Buy |
465,504
+18,256
| +4% | +$506K | 0.01% | 828 |
|
|
2020
Q1 | $12.3M | Buy |
447,248
+350,722
| +363% | +$10.5M | 0.01% | 808 |
|
|
2019
Q4 | $2.82M | Buy |
96,526
+3,790
| +4% | +$90.3K | ﹤0.01% | 1449 |
|
|
2019
Q3 | $1.77M | Buy |
92,736
+19,510
| +27% | +$458K | ﹤0.01% | 1666 |
|
|
2019
Q2 | $1.61M | Buy |
73,226
+8,549
| +13% | +$188K | ﹤0.01% | 1690 |
|
|
2019
Q1 | $1.32M | Buy |
64,677
+8,098
| +14% | +$141K | ﹤0.01% | 1706 |
|
|
2018
Q4 | $713K | Buy |
56,579
+32,679
| +137% | +$487K | ﹤0.01% | 1865 |
|
|
2018
Q3 | $367K | Hold |
23,900
| – | – | ﹤0.01% | 2211 |
|
|
2018
Q2 | $313K | Buy |
+23,900
| New | +$263K | ﹤0.01% | 2280 |
|
|
2016
Q4 | – | Sell |
-25,600
| Closed | -$210K | – | 2600 |
|
|
2016
Q3 | $210K | Hold |
25,600
| – | – | ﹤0.01% | 2440 |
|
|
2016
Q2 | $206K | Buy |
+25,600
| New | +$205K | ﹤0.01% | 2429 |
|
Other funds holding NEO
FLAM
GF
NAMI
B
UBS AM's NEO Position: Q2 2026 in Review
UBS AM reduced its NeoGenomics (NEO) stake by 0.61% in Q2 2026, selling an estimated $21.1K and leaving 357,728 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1589.
UBS AM first reported a position in NEO in Q2 2016 and has held it in 34 quarters since. The position peaked at $24.5M in Q4 2020. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.
- UBS AM held 357,728 shares of NeoGenomics worth $5.22M as of Q2 2026.
- UBS AM sold 2,185 NeoGenomics shares in Q2 2026, an estimated $21.1K.
- NeoGenomics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1589 holding.
- UBS AM first reported a position in NeoGenomics in Q2 2016 and has held it in 34 quarters since.
- UBS AM's NeoGenomics position peaked at $24.5M in Q4 2020.
- 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.